Company Overview of OvaScience, Inc.
OvaScience, Inc., a life sciences company, is engaged in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor cells (EggPCs), which are found in the ovaries. It is developing various fertility treatment options designed to enhance egg quality and in vitro fertilization (IVF) comprising AUGMENT to improve egg quality and increase the success of IVF by transferring mitochondria from a woman's EggPCs to her mature egg during IVF; OvaPrime for boosting a woman's egg reserve by transferring the EggPCs from the outer layer of her ovary back into the ovary prior to IVF; OvaTure to create mat...
215 First Street
Cambridge, MA 02142
Founded in 2011
Key Executives for OvaScience, Inc.
Chief Commercial Officer and Head of Sales & Marketing
Total Annual Compensation: $310.0K
Chief Scientific Officer
Total Annual Compensation: $106.3K
Compensation as of Fiscal Year 2013.
OvaScience, Inc. Key Developments
OvaScience Appoints Jeffrey Young as Chief Financial Officer
Sep 18 14
OvaScience announced the appointment of Jeffrey Young to Chief Financial Officer. Mr. Young joins OvaScience from Transmedics, Inc., where he served as Chief Financial Officer and Treasurer, leading the finance, accounting, tax and treasury functions. Prior to serving as CFO of Transmedics, Mr. Young was CFO and Treasurer at Lantheus Medical Imaging, Inc. While at Lantheus, an international corporation, he was responsible for multiple functions, including finance, accounting, customer service, tax and treasury.
OvaScience, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014
Aug 7 14
OvaScience, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations was of $9.595 million compared to $6.021 million a year ago. Net loss applicable to common stockholders was of $9.893 million or $0.42 per basic and diluted share compared to $5.996 million or $0.36 per basic and diluted share a year ago.
For six months, the company reported loss from operations was of $17.245 million compared to $11.196 million a year ago. Net loss applicable to common stockholders was of $17.707 million or $0.83 per basic and diluted share compared to $11.153 million or $0.74 per basic and diluted share a year ago.
OvaScience, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 08:35 AM
Jul 24 14
OvaScience, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 08:35 AM. Venue: Le Parker Meridien, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|